Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 18/20 | 0.51 |
| ▸ | JAK1 | P23458 | 18/20 | 0.51 |
| ▸ | TYK2 | P29597 | 18/20 | 0.51 |
| ▸ | JAK3 | P52333 | 18/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29619880 | 0.99 | PTGER4 (0.55) | PTGER4KMT2AJAK2JAK1TYK2 | |
| Bromide SCHEMBL28608182 | 0.99 | PTGER4 (0.55) | PTGER4KMT2AJAK2JAK1TYK2 | |
| SCHEMBL22121416 | 0.89 | KMT2A (0.57) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL19436565 | 0.85 | PTGER4 (0.55) | PTGER4KMT2AJAK2JAK1TYK2 | |
| SCHEMBL23346485 | 0.83 | PTGER4 (0.53) | PTGER4KMT2AJAK2JAK1TYK2 | |
| SCHEMBL19448908 | 0.82 | PTGER4 (0.55) | PTGER4KMT2AJAK2JAK1TYK2 | |
| SCHEMBL19437503 | 0.82 | KMT2A (0.74) | PTGER4KMT2AJAK2JAK1TYK2 | |
| SCHEMBL19436566 | 0.82 | JAK2 (0.62) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL19436506 | 0.82 | JAK2 (0.62) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL22121361 | 0.81 | KMT2A (0.54) | KMT2AJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111417630-B | Modulators of interferon gene stimulating factor (STING) | 葛兰素史克知识产权开发有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-3440076-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| CN-113549110-A | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-109608443-B | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-109071514-B | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-10981901-B1 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| EP-3440072-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| WO-2019069270-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| EP-3440076-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| EP-3440072-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-10189820-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| WO-2017175156-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175156-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175147-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175147-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189820-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | PTGER4 3619/4885KMT2A 1428/4885JAK2 2724/4885 |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | PTGER4 3619/4885KMT2A 1428/4885JAK2 2724/4885 |
| US-10981901-B1 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | PTGER4 3619/4885KMT2A 1428/4885JAK2 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.